Medidata Solutions

Medidata Solutions is a global life sciences technology provider to improve the way clinical research is designed, conducted, analyzed, and commercialized. The company's cloud-based platform of solutions, data analytics, and AI improves quality throughout clinical development programs. The company's Medidata Cloud provides a platform for demonstrating treatment efficacy and safety, supporting regulatory approval, improving outcomes for patients, providers, and payers. It has data capture, management, and reporting family of solutions. The company's services offerings include implementation services, sponsor enablement, strategic consulting, partner support, e-learning and training, and ongoing support.
  • TickerMDSO
  • ISINUS58471A1051
  • ExchangeNASDAQ Stock Market
  • SectorSoftware & Computer Services
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for MDSO

ValuEngine Rating and Forecast Report for MDSO

A double requalification allows MEDIDATA SOLUTIONS INCO. to improve to Slightly Positive

MEDIDATA SOLUTIONS INCO. (US), a company active in the Software industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation is now 2 out of 4 stars while its market behaviour can be considered as defensive. theScreener believes that the gain of a star(s) and an improvement in the market risk perception allows upgrading the general evaluation to Slightly Positive. As of the analysis date October 8, 2019, the closing price was USD 91.62 and its potential was estimated at USD 103.74.

ValuEngine Rating and Forecast Report for MDSO

ValuEngine Rating and Forecast Report for MDSO

Valens Research

UAFRS vs As Reported Weekly Highlights - 2019 06 12

This week, Valens identified distortions and the corresponding adjustments to correct for those distortions for IQV, MDSO, and WSP:CAN.

Jonathan Moreland

InsiderInsights Daily Ratings Report: October 25, 2018

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ValuEngine Rating and Forecast Report for MDSO

ValuEngine Rating and Forecast Report for MDSO

A double requalification allows MEDIDATA SOLUTIONS INCO. to improve to Slightly Positive

MEDIDATA SOLUTIONS INCO. (US), a company active in the Software industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation is now 2 out of 4 stars while its market behaviour can be considered as defensive. theScreener believes that the gain of a star(s) and an improvement in the market risk perception allows upgrading the general evaluation to Slightly Positive. As of the analysis date October 8, 2019, the closing price was USD 91.62 and its potential was estimated at USD 103.74.

ValuEngine Rating and Forecast Report for MDSO

ValuEngine Rating and Forecast Report for MDSO

ValuEngine Rating and Forecast Report for MDSO

ValuEngine Rating and Forecast Report for MDSO

ValuEngine Rating and Forecast Report for MDSO

ValuEngine Rating and Forecast Report for MDSO

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Gold appears to be developing a potential head-and-shoulders bottom. A break above the $128 level would be very bullish. (ex. GLD and GDX) • A number of restaurants are bullishly inflecting, trending up and to the right. (ex. JACK, DIN, SHAK, and YUM) • REIT's continue to be leadership (ex. PSB, HCP, HR, WELL, ARE, ESS, MAA, AMT, CCI, and SBAC)

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

As higher lows continue within a broader YTD sideways consolidation, the S&P 500 is poised to retest the 2,790-2,800 horizontal resistance level that we have highlighted in previous reports. While we continue to expect the broad YTD consolidation to continue, below we highlight additional factors that lead to our overall constructive outlook: • XLF bouncing off critical support with authority. We have voiced our concern regarding a potential breakdown below $26.50 on the XLF and the negative implications that it would have on the broad market. We have also noted a failure to break down woul...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch